Acolbifene/prasterone - Endoceutics
Alternative Names: Dehydroepiandrosterone/Acolbifene; DHEA/Acolbifene; Femivia; Prasterone/AcolbifeneLatest Information Update: 07 Dec 2022
At a glance
- Originator Endoceutics
- Class Androstenols; Antineoplastics; Benzopyrans; Osteoporosis therapies; Phenyl ethers; Piperidines; Small molecules
- Mechanism of Action Dehydroepiandrosterone replacements; Selective estrogen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Vasomotor symptoms
- No development reported Osteoporosis
- Discontinued Breast cancer; Decreased libido; Hypogonadism
Most Recent Events
- 07 Dec 2022 No development reported - Phase-III for Osteoporosis (Prevention) in Canada (PO) (Endoceutics website, December 2022)
- 22 Oct 2020 Discontinued - Phase-III for Decreased libido in Canada (PO) (Endoceutics' pipeline, October 2020)
- 22 Oct 2020 Discontinued - Phase-III for Hypogonadism in Canada (PO) (Endoceutics' pipeline, October 2020)